Medical Treatment of Benign Prostatic Hyperplasia - ymf.org.tw

50

(remodeling)remodeling))

20 30 30

65

(remodeling) : )

: : / :

D B B12 K

50

Normal men1 Late menopausal women1 Early menopausal women1

0.5% 1.0% 2.0% 2.6% AI therapy in PMW2 3.3%

Bone marrow transplant3 4.6% Androgen-deprivation therapy4 7.0% AI therapy plus GnRH agonist5 Ovarian failure

secondary to chemotherapy6 7.7% 0 2 4 6 8 Lumbar spine BMD loss at 1 year, %

AI; aromatase inhibitor; GnRH, g)onadotropin-releasing) hormone; PMW, postmenopausal women. 1. Kanis JA. In: Osteoporosis. Blackwell Healthcare Communications Ltd, 1997; 2. Eastell R, et al. J Bone Miner Res. 2006;21(remodeling)8):1215-1223; 3. Lee WY, et al. J Clin Endocrinol Metab. 2002;87(remodeling)1):329-335; 4. Maillefert JF, et al. J Urol. 1999;161(remodeling)4):1219-1222; 5. Gnant M, et al. Breast Cancer Res Treat. 2002;76(remodeling)suppl 1):S31. Abstract 12; 6. Shapiro CL, et al. J Clin Oncol. 2001;19(remodeling)14):3306-3311.

50

90% 30%

T-score, SD

1 1 2.5 2.5 2.5 1 fracture 1 SD 1.5 2.5

30 National Osteoporosis Foundation, 2003.Kanis JA, et al. J Bone Miner Res. 1994;9:1137-1141. (mg/mg/

cm2)) > 833 1 (remodeling)BMD -1 SD) 648833

1 2.5 (remodeling)-2.5 SD BMD < -1 SD) < 648 2.5

(remodeling)BMD < -2.5 SD) Osteopenia Osteoporosis Severe osteoporosis 2.5

,

(remodeling) , )

D Fosamax (remodeling) ) :

: , Zoledronic Acid (remodeling) )

, ,

50 1200

800 / 1200 / 40 1000 / 40 1500 /

60 1000 / 60 1200 /

100 cc 100 cc 100 g) 100 g) 100 g) 100 g)

30 g) 118 mg) 124 mg) 160 mg) 721 mg) 461 mg) 160 mg) 33 mg)

D D 400 800 15

56

1 500 +31 -120 2

500 +24 -116 3 800

+12 -85 4 1400 +10

-84 5 1400 +20 -65

920 +19 -94 2 3

D (remodeling) )